Multi-Modality Echocardiographic Techniques in Pathological Left Ventricular Hypertrophy Adults
NCT ID: NCT05719337
Last Updated: 2023-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
660 participants
OBSERVATIONAL
2023-01-01
2025-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Clinical Research of the Safety and Effectiveness Evaluation for Using Echocardiography-guided Liwen RF Radiofrequency Ablation System to Treat Hypertrophic Obstructive Cardiomyopathy
NCT04355260
Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy
NCT05713916
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065
Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction
NCT06196086
Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data.
NCT05942729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with LVH commonly associate with left ventricular diastolic dysfunction, causing changes in the structure and function of the left atrium prior to abnormal left ventricular ejection fraction. Left atrium function at reservoir, conduit and booster phases can be noninvasively quantify by speckle tracking echocardiography. However, there is incomplete information on left atrium strain characteristics in patients with LV pathological hypertrophy. The myocardial longitudinal strain parameters derived from speckle tracking echocardiography is a sensitive noninvasive method of assessing left ventricular myocardial performance. The relative "apical sparing" can be easily visualized for patients with cardiac amyloidosis. The reduced longitudinal strain in the basal lateral wall could be found at the very early stages of Fabry disease. Hence the specific manifestations derived from longitudinal strain mapping can assist in the differentiate patients from various causes of LVH. And left ventricular volume and mass index assessed by three-dimension echocardiography are independently associated with adverse outcomes of LVH patients. Therefore, appropriate utilization of multi-modality echocardiography techniques is fundamental to accurate diagnosis as well as longitudinal care of pathological LVH patients. However, a great deal of studies were based on small samples and single center. There is lack of defined diagnostic results based on multi-modality echocardiography and comprehensive markers derived from large-scale study.
In this study, we expected to provide a set of parameters for different etiology by including patients with different pathological LVH based on multi-modality echocardiography, so as to assisting in early identification and risk assessment in LVH patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypertensive heart disease group
Systolic blood pressure exceeded 140 mmHg and/or diastolic blood pressure exceeded 90 mmHg, or a history of systemic hypertension in the absence of other cardiac or systemic disease was described as hypertension.
Echocardiography
Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Hypertrophic cardiomyopathy group
Wall thickness≥15 mm in the absence of other causes of hypertrophy in a non-dilated left ventricle (LV) defines HCM. End diastolic wall thickness≥13 mm can be diagnostic if there is a family history of HCM or a known disease-causing genetic mutation.
Echocardiography
Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Cardiac amyloidosis group
Clinical diagnosis of cardiac amyloidosis confirmed by blood tests or tissue biopsy.
Echocardiography
Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Fabry disease group
Clinical diagnosis of Fabray disease confirmed by blood biomarkers or genetic testing.
Echocardiography
Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echocardiography
Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A wall thickness ≥ 12mm in one or more LV myocardial segments as measured by 2D echocardiography.
* Patients with definite diagnosis of hypertensive heart disease, hypertrophic cardiomyopathy, cardiac amyloidosis or Fabry disease.
Exclusion Criteria
* Hypertrophy of myocardium caused by high intensity exercise;
* Poor ultrasonic image quality, which cannot meet analysis requirement.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
First Hospital of China Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chunyan Ma
Chief of Cardiovascular Ultrasound
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chunyan Ma, Ph.D
Role: PRINCIPAL_INVESTIGATOR
the First Hospital of China Medical Univeristy
Li Zhang, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
the First Affiliated Hospital of Jiamusi University
Jiamusi, Heilongjiang, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
the Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Ansteel Group General Hospita
Anshan, Liaoning, China
Benxi Central Hospital
Benxi, Liaoning, China
Chaoyang Central Hospital
Chaoyang, Liaoning, China
Dalian Municipal Central Hospital
Dalian, Liaoning, China
the Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Dandong Central Hospital
Dandong, Liaoning, China
Fushun Central Hospital
Fushun, Liaoning, China
the First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
Affiliated Central Hospital of Shenyang Medical College
Shenyang, Liaoning, China
Dadong Branch of First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Shenyang, Liaoning, China
the First Hospital of China Medical Univeristy
Shenyang, Liaoning, China
the Second Affiliated Hospital of Shenyang Medical College
Shenyang, Liaoning, China
Liao Jian Group Tie Mei General Hospital
Tieling, Liaoning, China
Tieling Central Hospital
Tieling, Liaoning, China
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hongning Yin
Role: primary
Xin Yang
Role: primary
Li Zhang, Ph.D
Role: primary
Xiaoshan Zhang
Role: primary
Jing Yao
Role: primary
Ying Liu, Ph.D
Role: primary
Xingbin Wang
Role: primary
Guixin Zhu
Role: primary
Qingxiong Yue
Role: primary
Yuhong Zhang
Role: primary
Xin Jin
Role: primary
Chen Zhang
Role: primary
Yuhong Li
Role: primary
Tong Zang
Role: primary
Jiahui Ma
Role: primary
Kuiran Gao
Role: primary
Linwei Hong
Role: primary
Chunyan Ma, Ph.D
Role: primary
Ying Ding
Role: primary
Sha Li
Role: primary
Jie Liang
Role: primary
Xin Guan
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MET-LVH-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.